CoChat
Sign Up
Cited by 293Parkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on BehaviorNeural and Behavioral Psychology Studies

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease

Open access
Tessitore, Alessandro, Hariri, Ahmad R., Fera, Francesco, Smith, William G., Chase, Thomas N., Hyde, Thomas M., Weinberger, Daniel R., Mattay, Venkata S.·2002·The Journal of Neuroscience
DOI 10.1523/jneurosci.22-20-09099.2002PMC PMC6757686
Open this paper in CoChat — free accountOpen PDF

Abstract

In addition to classic motor signs and symptoms, Parkinson's disease (PD) is characterized by neuropsychological and emotional deficits, including a blunted emotional response. In the present study, we explored both the neural basis of abnormal emotional behavior in PD and the physiological effects of dopaminergic therapy on the response of the amygdala, a central structure in emotion processing. PD patients and matched normal controls (NCs) were studied with blood oxygenation level-dependent functional magnetic resonance imaging during a paradigm that involved perceptual processing of fearful stimuli. PD patients were studied twice, once during a relatively hypodopaminergic state (i.e., > or =12 hr after their last dose of dopamimetic treatment) and again during a dopamine-replete state. The imaging data revealed a robust bilateral amygdala response in NCs that was absent in PD patients during the hypodopaminergic state. Dopamine repletion partially restored this response in PD patients. Our results demonstrate an abnormal amygdala response in PD that may underlie the emotional deficits accompanying the disease. Furthermore, consistent with findings in experimental animal paradigms, our results provide in vivo evidence of the role of dopamine in modulating the response of the amygdala to sensory information in human subjects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.22-20-09099.2002

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Hariri AR, Mattay VS, Tessitore A, Fera F, Smith WG, Weinberger DR (2002) Dextroamphetamine potentiates the human amygdala response to fearful stimuli. Neuropsychopharmacology, in press.

Cited by

Sorted by citations

See all 293

Related

See all

Metadata

Authors
Tessitore, A., Hariri, A. R., Fera, F., Smith, W. G., Chase, T. N., Hyde, T. M., Weinberger, D. R., & Mattay, V. S.
Affiliations
  • National Institute of Mental Health (US)
  • National Institutes of Health (US)
ORCID
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2002-10-15
Volume
22
Issue
20
Pages
9099-9103
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
DOI
10.1523/jneurosci.22-20-09099.2002
PMC
PMC6757686
OpenAlex
W2158459330
Cited by
293
References
47
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 3 · 2022: 4 · 2021: 13 · 2020: 6 · 2019: 9 · 2018: 16 · 2017: 15 · 2016: 15 · 2015: 18 · 2014: 18 · 2013: 13 · 2012: 15
FWCI
5.97
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
Keywords
Parkinson's disease, dopamine, amygdala, emotional deficits, fear processing, dopaminergic therapy, hypodopaminergic state, emotional processing, functional MRI
MeSH terms
Amygdala, Antiparkinson Agents, Behavior, Brain Mapping, Dopamine, Drug Therapy, Combination, Emotions, Facial Expression, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease, Pattern Recognition, Visual, Photic Stimulation, Reaction Time, Reference Values, Dopamine Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review